Full Prescribing Information for DURAGESIC® (fentanyl transdermal
... Due to the risk of respiratory depression, DURAGESIC is only indicated for use in patients who are already opioid-tolerant. Discontinue or taper all other extended-release opioids when beginning DURAGESIC therapy. As DURAGESIC is only for use in opioid-tolerant patients, do not begin any patient on ...
... Due to the risk of respiratory depression, DURAGESIC is only indicated for use in patients who are already opioid-tolerant. Discontinue or taper all other extended-release opioids when beginning DURAGESIC therapy. As DURAGESIC is only for use in opioid-tolerant patients, do not begin any patient on ...
Prescribing Information
... In patients who are not eligible for auto-HSCT, treatment should continue until disease progression or unacceptable toxicity. For patients who are auto-HSCT-eligible, hematopoietic stem cell mobilization should occur within 4 cycles of a REVLIMID-containing therapy [see Warnings and Precautions (5.1 ...
... In patients who are not eligible for auto-HSCT, treatment should continue until disease progression or unacceptable toxicity. For patients who are auto-HSCT-eligible, hematopoietic stem cell mobilization should occur within 4 cycles of a REVLIMID-containing therapy [see Warnings and Precautions (5.1 ...
Leptospirosis Presenting as Diffuse Alveolar Hemorrhage Dr Mary
... culture showed normal flora. He had raised IGM leptospiral antibody titres. With a clinical diagnosis of leptospirosis, hepatorenal involvement and pulmonary involvement in the form of diffuse alveolar hemorrhage, he was started on injection crystalline penicillin and methyl prednisolone .He was als ...
... culture showed normal flora. He had raised IGM leptospiral antibody titres. With a clinical diagnosis of leptospirosis, hepatorenal involvement and pulmonary involvement in the form of diffuse alveolar hemorrhage, he was started on injection crystalline penicillin and methyl prednisolone .He was als ...
Selecting the Optimal Oral Antihistamine for Patients with Allergic
... now recognised that AR has a significant impact on the quality of life (QOL) of those who experience it. A major condition commonly encountered as a result of AR is sleep disturbance. Failure to get a good night’s sleep as a result of symptoms of AR can cause significant impairment in daily activiti ...
... now recognised that AR has a significant impact on the quality of life (QOL) of those who experience it. A major condition commonly encountered as a result of AR is sleep disturbance. Failure to get a good night’s sleep as a result of symptoms of AR can cause significant impairment in daily activiti ...
Tardive dystonia - The Dystonia Society
... serious mental health conditions such as schizophrenia or psychosis where they have been found in many cases to have a positive effect. These drugs may also be used for the treatment of some movement disorders such as severe chorea and tics. This family of drugs are called ‘dopamine receptor blockin ...
... serious mental health conditions such as schizophrenia or psychosis where they have been found in many cases to have a positive effect. These drugs may also be used for the treatment of some movement disorders such as severe chorea and tics. This family of drugs are called ‘dopamine receptor blockin ...
SINEMET
... SINEMET may be given to patients already receiving levodopa alone; however, the levodopa alone must be discontinued 12 hours before SINEMET is started. SINEMET should be substituted at a dosage that will provide approximately 20 percent of the previous levodopa dosage (see DOSAGE AND ADMINISTRATION) ...
... SINEMET may be given to patients already receiving levodopa alone; however, the levodopa alone must be discontinued 12 hours before SINEMET is started. SINEMET should be substituted at a dosage that will provide approximately 20 percent of the previous levodopa dosage (see DOSAGE AND ADMINISTRATION) ...
Final Protocol - Word 730 KB - Medical Services Advisory Committee
... minimise side effects of treatment, and improve quality of life. Non-surgical treatment for Crohn’s disease includes dietary measures and drug therapy. Corticosteroids, antibiotics and anti TNF agents are used to induce remission, and immunosuppressive agents or maintenance anti TNF therapy to maint ...
... minimise side effects of treatment, and improve quality of life. Non-surgical treatment for Crohn’s disease includes dietary measures and drug therapy. Corticosteroids, antibiotics and anti TNF agents are used to induce remission, and immunosuppressive agents or maintenance anti TNF therapy to maint ...
Acute Canine Gastroenteritis
... Marked viremia usually, but not always, manifested by intestinal disease ...
... Marked viremia usually, but not always, manifested by intestinal disease ...
... colony-stimulating factor (GM-CSF; stimulator of granulopoiesis and monopoiesis) [48, 49], and monocyte colony-stimulating factor (M-CSF; stimulator of monocyte proliferation) [50]. The relative contributions of the lymphokines to granuloma formation are not known. Tissue immunohistochemistry studie ...
Oncologic Emergencies, Part I: Spinal Cord Compression, Superior
... about the following 6 subjects: (1) the type of cancer they have and whether there are known metastases; (2) whether they have undergone or are undergoing radiation therapy or chemotherapy; (3) the results of previous imaging studies; (4) recent trauma; (5) risk factors that might point to other cau ...
... about the following 6 subjects: (1) the type of cancer they have and whether there are known metastases; (2) whether they have undergone or are undergoing radiation therapy or chemotherapy; (3) the results of previous imaging studies; (4) recent trauma; (5) risk factors that might point to other cau ...
Lysosomal storage diseases: Diagnostic confirmation
... cells can integrate into many tissues, including the CNS. The disadvantages include the low level of correction and the time required for integration of the cells into other tissues, factors that currently preclude HSCT from being curative. Specific treatments for LSDs are evolving rapidly with the ...
... cells can integrate into many tissues, including the CNS. The disadvantages include the low level of correction and the time required for integration of the cells into other tissues, factors that currently preclude HSCT from being curative. Specific treatments for LSDs are evolving rapidly with the ...
Chapter 152 - Cardiovascular Drugs
... These mechanisms account for an increase in premature ventricular contractions, the most common manifestation of digoxin toxicity. At toxic extremes, these effects result in a dangerous sensitivity to mechanical and electrical stimulation. Interventions with pacemaker wires, catheters, and cardiover ...
... These mechanisms account for an increase in premature ventricular contractions, the most common manifestation of digoxin toxicity. At toxic extremes, these effects result in a dangerous sensitivity to mechanical and electrical stimulation. Interventions with pacemaker wires, catheters, and cardiover ...
highlights of prescribing information
... infant. When Humatrope is to be administered to a newborn infant it should be reconstituted with the diluent provided or, if the infant is sensitive to the diluent, Sterile Water for Injection, USP. When reconstituted with Sterile Water for Injection the solution should be kept refrigerated at 36° t ...
... infant. When Humatrope is to be administered to a newborn infant it should be reconstituted with the diluent provided or, if the infant is sensitive to the diluent, Sterile Water for Injection, USP. When reconstituted with Sterile Water for Injection the solution should be kept refrigerated at 36° t ...
Comparison of Aerobic Bacteria Isolation among Symptomatic and
... 12. Vishal Sharma, Vishal Gupta, Mridula mittal. Prevalence of uropathogens in Diabetic patients and their antimicrobial susceptibility pattern. National Journal of Laboratory Medicine. 2012 June; 1(1): 26-28. ...
... 12. Vishal Sharma, Vishal Gupta, Mridula mittal. Prevalence of uropathogens in Diabetic patients and their antimicrobial susceptibility pattern. National Journal of Laboratory Medicine. 2012 June; 1(1): 26-28. ...
Psychobiotics: The Potential Therapeutic Promise of Microbes in
... guided by the immune system of the host 1 . Probiotic therapy is the application of potentially beneficial microorganisms to support the balance of beneficial and harmful microbiota in our body system2. The probiotic microorganisms not only compete with the pathogens of the host but also improve the ...
... guided by the immune system of the host 1 . Probiotic therapy is the application of potentially beneficial microorganisms to support the balance of beneficial and harmful microbiota in our body system2. The probiotic microorganisms not only compete with the pathogens of the host but also improve the ...
Lysosomal storage diseases: Diagnostic confirmation and
... cells can integrate into many tissues, including the CNS. The disadvantages include the low level of correction and the time required for integration of the cells into other tissues, factors that currently preclude HSCT from being curative. Specific treatments for LSDs are evolving rapidly with the ...
... cells can integrate into many tissues, including the CNS. The disadvantages include the low level of correction and the time required for integration of the cells into other tissues, factors that currently preclude HSCT from being curative. Specific treatments for LSDs are evolving rapidly with the ...
Inhaler Sequence
... subsequently reported the same results as did group one. They (the physicians of that ractice) expressed their astonishment at the change and lauded my recommendations. They did not study their patients in a 'formal' enough manner to report their findings in the form of a paper. But, they were convi ...
... subsequently reported the same results as did group one. They (the physicians of that ractice) expressed their astonishment at the change and lauded my recommendations. They did not study their patients in a 'formal' enough manner to report their findings in the form of a paper. But, they were convi ...
highlights of prescribing information
... infant. When Humatrope is to be administered to a newborn infant it should be reconstituted with the diluent provided or, if the infant is sensitive to the diluent, Sterile Water for Injection, USP. When reconstituted with Sterile Water for Injection the solution should be kept refrigerated at 36° t ...
... infant. When Humatrope is to be administered to a newborn infant it should be reconstituted with the diluent provided or, if the infant is sensitive to the diluent, Sterile Water for Injection, USP. When reconstituted with Sterile Water for Injection the solution should be kept refrigerated at 36° t ...
I IIa IIb III IIa IIb III - Preventive Cardiovascular Nurses Association
... exercise test, to guide prescription I IIa IIb III ...
... exercise test, to guide prescription I IIa IIb III ...
Guidelines for the Use of Antiretroviral Agents in Adults
... 1. 3TC can be used in place of FTC and vice versa. 2. ABC should not be used in patients who test positive for HLA-B*5701; caution if HIV RNA >100,000 copies/mL, or if high risk of cardiovascular disease. 3. NVP and ABC both can cause hypersensitivity reaction in first few weeks of treatment. 4. NVP ...
... 1. 3TC can be used in place of FTC and vice versa. 2. ABC should not be used in patients who test positive for HLA-B*5701; caution if HIV RNA >100,000 copies/mL, or if high risk of cardiovascular disease. 3. NVP and ABC both can cause hypersensitivity reaction in first few weeks of treatment. 4. NVP ...
National Institute for Health and Clinical Excellence
... groups of patients for the purposes of treatment and research.” The guidelines appear to recognise the heterogeneous nature of the illness, but then fail to address sub grouping under the CFS/ME “umbrella”, and offer a ‘one treatment fits all’ approach. Many of the research papers used to inform the ...
... groups of patients for the purposes of treatment and research.” The guidelines appear to recognise the heterogeneous nature of the illness, but then fail to address sub grouping under the CFS/ME “umbrella”, and offer a ‘one treatment fits all’ approach. Many of the research papers used to inform the ...
Ocular Allergy and Dry Eye File - HealthLearn
... olopatadine (Patanol, Alcon Laboratories) (Table above).2 Introduced in 1997, Patanol ...
... olopatadine (Patanol, Alcon Laboratories) (Table above).2 Introduced in 1997, Patanol ...
Guillain-Barre Syndrome - Guillain Barré Syndrome Support Group
... proteins with peripheral nerve proteins (antigens) and it is known that the immune response to the C. jejuni bacterium then involves the nerve because of this “molecular mimicry”. It is thought that the same mechanism may be operating following other infections but no common antigen has been found. ...
... proteins with peripheral nerve proteins (antigens) and it is known that the immune response to the C. jejuni bacterium then involves the nerve because of this “molecular mimicry”. It is thought that the same mechanism may be operating following other infections but no common antigen has been found. ...
Management of multiple sclerosis
Several therapies for multiple sclerosis (MS) exist, although there is no known cure. Multiple sclerosis is a chronic inflammatory demyelinating disease that affects the central nervous system (CNS).The most common initial course of the disease is the relapsing-remitting subtype, which is characterized by unpredictable attacks (relapses) followed by periods of relative remission with no new signs of disease activity. After some years, many of the people who have this subtype begin to experience neurologic decline without acute relapses. When this happens it is called secondary progressive multiple sclerosis. Other, less common, courses of the disease are the primary progressive (decline from the beginning without attacks) and the progressive-relapsing (steady neurologic decline and superimposed attacks). Different therapies are used for patients experiencing acute attacks, for patients who have the relapsing-remitting subtype, for patients who have the progressive subtypes, for patients without a diagnosis of MS who have a demyelinating event, and for managing the various consequences of MS.The primary aims of therapy are returning function after an attack, preventing new attacks, and preventing disability. As with any medical treatment, medications used in the management of MS may have several adverse effects, and many possible therapies are still under investigation. At the same time different alternative treatments are pursued by many patients, despite the paucity of supporting, comparable, replicated scientific study.This article focuses on therapies for standard MS; borderline forms of MS have particular treatments that are excluded.